Zimmer Biomet Holdings Inc
NYSE:ZBH
Intrinsic Value
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. [ Read More ]
The intrinsic value of one
ZBH
stock under the Base Case scenario is
148.3
USD.
Compared to the current market price of 119.74 USD,
Zimmer Biomet Holdings Inc
is
Undervalued by 19%.
Zimmer Biomet Holdings Inc's market capitalization is 24.6B USD.
ZBH stock price is 119.74 USD.
ZBH stock price (119.74 USD) is 19% less than its Intrinsic Value (148.3 USD).
ZBH stock price (119.74 USD) is 35% less than its Relative Value (184.72 USD). Open Relative Valuation
ZBH has upside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
ZBH's Revenue has been growing by 2% per year for the last 3 years.
ZBH's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
ZBH's Revenue has grown by 7% over the past 12 months.
ZBH's ROIC (Return on Invested Capital) has increased in the last 3 years from 5% to 7%.
ZBH's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
ZBH's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
ZBH's ROE (Return on Equity) has increased in the last 3 years from 5% to 8%.
ZBH has positive Operating Income for the last twelve months.
ZBH has positive Net Income for the last twelve months.
ZBH has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
ZBH has a very low three-year average ROE (Return on Equity): 4%. The company is not efficient at transforming stockholders' equity into net income.
ZBH's short-term assets (5B USD) exceed its short-term liabilties (3B USD).
ZBH's Altman Z-Score is equal to 2.99.
ZBH has positive Free Cash Flow for the last twelve months.
ZBH's long-term assets (21B USD) exceed its long-term liabilties (9B USD).
ZBH generates enough operating income (1B USD) to cover interest payments on its debt (201m USD).
ZBH has positive Gross Profit for the last twelve months.
ZBH's D/E (Debt to Equity) is very low and is equal to 0.39.
ZBH has positive Net Debt. This means that the company has more debt (5B USD) than cash and short-term investments (416m USD).
Valuation Backtest
Zimmer Biomet Holdings Inc
Run backtest to discover the historical profit from buying and selling
ZBH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Zimmer Biomet Holdings Inc
Balance Sheet Decomposition
Zimmer Biomet Holdings Inc
| Current Assets | 4.6B |
| Cash & Short-Term Investments | 415.8m |
| Receivables | 1.4B |
| Other Current Assets | 2.8B |
| Non-Current Assets | 16.9B |
| PP&E | 2.1B |
| Intangibles | 13.7B |
| Other Non-Current Assets | 1.2B |
| Current Liabilities | 2.9B |
| Accounts Payable | 410.6m |
| Accrued Liabilities | 417.1m |
| Other Current Liabilities | 2B |
| Non-Current Liabilities | 6.2B |
| Long-Term Debt | 4.9B |
| Other Non-Current Liabilities | 1.3B |
Earnings Waterfall
Zimmer Biomet Holdings Inc
|
Revenue
|
7.4B
USD
|
|
Cost of Revenue
|
-2.1B
USD
|
|
Gross Profit
|
5.3B
USD
|
|
Operating Expenses
|
-3.8B
USD
|
|
Operating Income
|
1.5B
USD
|
|
Other Expenses
|
-448.9m
USD
|
|
Net Income
|
1B
USD
|
Free Cash Flow Analysis
Zimmer Biomet Holdings Inc
ZBH Profitability Score
Profitability Due Diligence
Zimmer Biomet Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Zimmer Biomet Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
ZBH Solvency Score
Solvency Due Diligence
Zimmer Biomet Holdings Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Zimmer Biomet Holdings Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZBH Price Targets Summary
Zimmer Biomet Holdings Inc
According to Wall Street analysts, the average 1-year price target for
ZBH
is 139.92 USD
with a low forecast of 110.09 USD and a high forecast of 168 USD.
Ownership
ZBH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ZBH Price
Zimmer Biomet Holdings Inc
| Average Annual Return | 3.57% |
| Standard Deviation of Annual Returns | 14.53% |
| Max Drawdown | -50% |
| Market Capitalization | 24.6B USD |
| Shares Outstanding | 205 460 992 |
| Percentage of Shares Shorted | 2.61% |
Company Profile
Zimmer Biomet Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 19,500 full-time employees. The company went IPO on 2001-07-25. The firm is engaged in the design, manufacture and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic (CMFT) products; dental implants, and related surgical products. The firm's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The company operates through four segments: Americas Orthopedics, Europe, Middle East and Africa (EMEA), Asia Pacific, and Americas Spine and Global Dental. Its knee brands include Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. Its S.E.T. brands include JuggerKnot Soft Anchor System, Gel-One1 Cross-linked Hyaluronate, Comprehensive Shoulder and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
ZBH
stock under the Base Case scenario is
148.3
USD.
Compared to the current market price of 119.74 USD,
Zimmer Biomet Holdings Inc
is
Undervalued by 19%.
You don't have any saved screeners yet
